Bellicum Pharmaceuticals Inc. Company Name:
BLCM Stock Symbol:
NASDAQ Market:
Bellicum Pharmaceuticals Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients wit...
HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been pl...
Strategic focus on clinical GoCAR-T ® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year Completed offering of shares of common stock plus warrants that raised gross proceeds of approximately...